Evercore ISI upgraded Cardinal Health (CAH) to Outperform from In Line with an unchanged price target of $140. The firm sees the company’s fiscal 2025 pharma guidance as conservative with upside to its long-term outlook. Looking forward, Cardinal has additional profit growth, partially offset by continued industry pricing headwinds, the analyst tells investors in a research note. These headwinds are largely known by investors, so slight underperformance going forward will not have a material impact, contends Evercore.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAH:
- McKesson price target lowered to $650 from $680 at BofA
- Cardinal Health upgraded to Buy from Neutral at BofA
- Cardinal Health price target raised to $136 from $127 at Morgan Stanley
- Salesforce upgraded, ServiceNow downgraded: Wall Street’s top analyst calls
- Wells upgrades Cardinal Health to Equal Weight with thesis played out